Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brent Stevenson

Sleep Medicine Frisco, TX Doctor of Osteopathy

NPI 1649204926 CMS profile 165729

3800 Gaylord Pkwy Ste 1190, Frisco, TX 75034

Open in the dashboard

General payments

$9,299

249 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brent Stevenson of Frisco, TX is reported in the CMS Open Payments database as having received $9,299 across 249 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Sleep Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,860 26
2024 General $1,527 52
2023 General $1,269 45
2022 General $723 29
2021 General $890 47
2020 General $571 31
2019 General $460 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brent Stevenson
  • Sleep Medicine median
  • Middle half of Sleep Medicine
  • National median

In program year 2025, general payments to Brent Stevenson were reported at $3,860. Among 263 Sleep Medicine profiles paid that year, the median was $337 and the middle half received between $114 and $1,241.

Show as a table
Year Brent Stevenson Sleep Medicine median Middle half National median
2019 $460 $206 $79–$855 $163
2020 $571 $170 $48–$1,437 $114
2021 $890 $178 $53–$1,297 $132
2022 $723 $313 $95–$1,332 $149
2023 $1,269 $307 $117–$1,081 $160
2024 $1,527 $308 $100–$1,432 $164
2025 $3,860 $337 $114–$1,241 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Axsome Therapeutics, Inc. $3,359 16 payments
  2. Jazz Pharmaceuticals Inc. $2,980 113 payments
  3. Harmony Biosciences LLC $1,072 55 payments
  4. Avadel CNS Pharmaceuticals, LLC $531 17 payments
  5. Inspire Medical Systems, Inc. $305 9 payments
  6. Respicardia, Inc. $235 3 payments
  7. Merck Sharp & Dohme Corporation $156 9 payments
  8. Idorsia Pharmaceuticals US Inc $143 8 payments
  9. Fisher & Paykel Healthcare Inc $127 4 payments
  10. Itamar Medical Inc $124 1 payment
  11. Other $268 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,149 245 payments
  2. Honoraria $2,925 1 payment
  3. Education $225 3 payments
Products named General payments · program years 2019–2025
  1. Sunosi Neurology $3,359 16 payments
  2. XYWAV $1,948 72 payments
  3. LUMRYZ $531 17 payments
  4. XYREM $505 18 payments
  5. Wakix Neurological Disorders $407 22 payments
  6. WAKIX Narcoplepsy $368 20 payments
  7. INSPIRE $305 9 payments
  8. SUNOSI Neurology $289 15 payments
  9. WAKIX Sleep Medicine $237 10 payments
  10. remede System $235 3 payments
  11. Other $1,646 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

796

Median for Psychiatry: 574

Drug cost

$295,014

Median for Psychiatry: $27,624

Branded share of claims

24%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xywav Sodium,calcium,mag,pot Oxybate Brand 15 $251,510
Belsomra Suvorexant Brand 30 $27,920
Armodafinil Generic 27 $2,887
Gabapentin Generic 160 $2,758
Pramipexole Dihydrochloride Pramipexole Di-Hcl Brand 117 $2,102
Modafinil Generic 26 $1,878
Zaleplon Generic 36 $1,127
Doxepin Hcl Generic 26 $950
Clonazepam Generic 95 $892
Zolpidem Tartrate Generic 78 $588

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$504,105

Medicare's payments for the services billed

Medicare patients

2,641

Average age 74

Services billed

7,730

1,058 women, 1,583 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 36%
Diabetes 30%
Atrial fibrillation 25%
Chronic kidney disease 22%
Depression 22%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XYWAV
  • JAZZ PHARMACEUTICALS INC. $409
$409 15 —
WAKIX
  • Harmony Biosciences LLC $368
$368 — —
LUMRYZ
  • Avadel CNS Pharmaceuticals, LLC $281
$281 — —
HORIZANT
  • CutisPharma, Inc. $63
$63 — —
Sunosi
  • Axsome Therapeutics, Inc. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

249 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sleep Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record